Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors,
with limited progress made in the area of myeloid malignancies. The low mutational burden …

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …

The combination of venetoclax (ven) and azacitidine (aza) has resulted in high response
rates in the upfront treatment of AML in patients age> 75 and patients unfit for intensive …

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients
with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax …

Simple Summary Venetoclax has proven to be a promising therapy for newly diagnosed,
relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing …

Recent advances in acute myeloid leukemia biology and drug development have
transformed the therapeutic landscape for patients diagnosed with this disease. By …

Background TP53 mutations, which are present in 5% to 10% of patients with acute myeloid
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …

Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an
effective treatment regimen for acute myeloid leukemia, in both de novo and …

Allogeneic hematopoietic stem cell transplantation (SCT) after a patient with acute myeloid
leukemia (AML) achieves a remission from intensive chemotherapy (IC) is given with …